Biosimulation Market Size, Growth & Forecast By 2033

Biosimulation technology is a computational approach that uses advanced software and algorithms to simulate biological systems, processes, and drug interactions. It allows researchers to create virtual models of the human body, diseases, and Pharmaceutical compounds, helping to predict how drugs will behave in real-world scenarios. By simulating various biological conditions, biosimulation enhances drug discovery, development, and testing, allowing for more accurate predictions of drug efficacy, safety, and patient outcomes.

Growing use of biosimulation in education and training creates tremendous opportunities

Biosimulation is becoming an essential tool in education and training, offering an engaging and innovative way for students, researchers, and healthcare professionals to explore complex biological systems in a virtual environment. This approach goes beyond traditional theory, allowing users to gain practical insights into drug behavior, biological pathways, protein interactions, and cellular signaling.

• For example, in 2022, the National Library of Medicine recognized the increasing role of simulation-based medical education (SBME) as a key part of undergraduate curricula, noting that it led to positive performance outcomes when integrated with traditional teaching methods.

By incorporating biosimulation into academic and professional training programs, educational institutions are better equipped to prepare the next generation of skilled professionals for the evolving healthcare and research fields.

North America holds the largest share of the global Biosimulation Market. This is primarily due to the strong presence of key players in the U.S. and Canada, who are investing heavily in research and development to introduce technologically advanced products. As a leader in innovation and technological advancements, North America is recognized for its pioneering role in the biosimulation market.

Moreover, the region's dominance is reinforced by its significant contribution to global clinical trials, with the United States leading the way, as reported by the WHO Clinical Trial Report, which recorded 157,618 registered trials from 1999 to 2021-far surpassing other countries like China and Japan, with 80,333 and 57,754 trials, respectively.

Key Highlights

• The global biosimulation market size was valued at USD 4.24 billion in 2024 and is expected to grow from USD 4.95 billion in 2025 to reach USD 17.02 billion by 2033, growing at a CAGR of 16.7% during the forecast period (2025 – 2033).
• Based on product, the global Biosimulation Market is divided into software and services. The software segment dominated the market with the largest market revenue.
• Based on applications, the global market is divided into drug discovery & development, disease modeling, and others drug discovery & development segment dominated the market with the largest market revenue.
• Based on deployment, the global Biosimulation Market is divided into cloud-based, on-premise, and hybrid models. The cloud-based segment dominated the market with the largest market revenue.
• Based on the therapeutic area insights, the global market is divided into oncology, cardiovascular disease, infection disease, neurological disorders, and others. The oncology segment dominated the market with the largest market revenue.
• Based on the pricing model, the global market is divided into the license-based model, subscription-based model, service-based model, and pay-per-use model. The license-based segment dominated the market with the largest market revenue.
• Based on end use, the global market is divided into life sciences companies, academic research institutions, and others life science company segment dominated the market with the largest market revenue.
• North America is the highest shareholder in the global biosimulation market.

The key players in the global market are Certara, Inc., Simulations Plus, Inc., Dassault Systèmes, BIOVIA (Dassault Systèmes), Schrodinger, Inc., Pharmalex, Roche, GSK (GlaxoSmithKline), AstraZeneca, Biorelate, Cyprotex, Accenture Life Sciences, Syneos Health, MaxCyte, InSilico Medicine, and others.

• In March 2024, Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, announced the results from a real-world study of gastroesophageal cancer, which found that Therapy Response Index (TRI) scores generated using the Cellworks Biosimulation Platform predicted overall survival (OS) above and beyond standard clinical factors, including patient age, sex, and tumor-node-metastasis (TNM) staging.